Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-γ production by human mononuclear cells

Clinical and Experimental Immunology

Volumn 149, Issue 1, 2007, Pages 178-185

  Chen, X ^a   O'Donnell, M A ^a   Luo, Y ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

BCG; Cytokine; IFN ; Th1

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL; WILD TYPE;

CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG SYNERGISM; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MYCOBACTERIUM BOVIS; RECOMBINANT PROTEINS; TH1 CELLS;

EID: 34250214973     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03413.x     Document Type: Article

References (45)

1. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 1980 124 : 38 40.
2. O'Donnell MA, DeWolf DC. Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 1995 4 : 189 202.
3. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999 353 : 1689 94.
4. Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992 19 : 573 80.
5. Dejager R, Guinan P, Lamm D. Long-term complete remission in bladder carcinoma in situ with intravesical Tice bacillus Calmette-Guérin. Urology 1991 38 : 507 13.
6. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003 169 : 96 100.
7. Steg A, Adjiman S, Debre B. BCG therapy in superficial bladder tumours - complications and precautions. Eur Urol 1992 21 (Suppl. 2 35 40.
8. Lamm DL, Van Der Meijden ADPM, Morales A et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992 147 : 596 600.
9. Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990 144 : 53 8.
10. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992 147 : 1636 42.
11. Peuchmaur M, Benoit G, Vieillefond A et al. Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus Calmette-Guérin. Urol Res 1989 17 : 299 303.
12. Saint F, Patard JJ, Groux Muscatelli B, et al. Evaluation of cellular tumor rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. BJU Int 2001 88 : 602 10.
13. De Boer EC, De Jong WH, Van Der Meijden AP et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother 1991 33 : 411 6.
14. De Boer EC, de Jong WH, van der Meijden AP et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 1991 19 : 45 50.
15. De Boer EC, De Jong WH, Steerenberg PA et al. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guérin. In Vivo 1991 5 : 671 7.
16. Bohle A, Nowc C, Ulmer AJ et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 1990 144 : 59 64.
17. de Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996 155 : 477 82.
18. Saint F, Patard JJ, Maille P et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer. J Urol 2002 167 : 364 7.
19. Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin. J Urol 2000 164 : 2129 33.
20. Poppas DP, Pavlovich CP, Folkman J et al. Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 1998 52 : 268 75.
21. Pavlovich CP, Kraling BM, Stewart RJ et al. BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation. J Urol 2000 163 : 2014 21.
22. Sanchez-Carbayo M, Urrutia M, Romani R et al. Serial urinary IL-2, IL-6, IL-8, TNF-alpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Anticancer Res 2001 21 : 3041 7.
23. Luo Y, Chen X, O'Donnell MA. Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 2007 147 : 370 8.
24. Saint F, Patard JJ, Maille P et al. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 2001 166 : 2142 7.
25. Nadler R, Luo Y, Zhao W et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. Clin Exp Immunol 2003 131 : 206 16.
26. Bercovich E, Deriu M, Manferrari F, Irianni G. BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl 1995 67 : 257 60.
27. Stricker P, Pryor K, Nicholson T et al. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urol 1996 48 : 957 61.
28. Clinton SK, Canto E, O'Donnell MA. Interleukin-12. opportunities for the treatment of bladder cancer. Urol Clin North Am 2000 27 : 147 55.
29. O'Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK. Role of IL-12 in the induction and potentiation of IFN-γ in response to bacillus Calmette-Guérin. J Immunol 1999 163 : 4246 52.
30. Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 1999 162 : 2399 405.
31. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. National BCG-Interferon Phase 2 Investigator Group. Urol Oncol 2006 24 : 344 8.
32. Joudi FN, O'Donnell MA. Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures. Curr Opin Urol 2004 14 : 271 5.
33. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol 2001 166 : 1300 4.
34. Luo Y, Chen X, O'Donnell MA. Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 2003 21 : 17 26.
35. O'Donnell MA, Aldovini A, Duda RB et al. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994 62 : 2508 14.
36. Luo Y, Chen X, Han R, O'Donnell MA. Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 2001 123 : 264 70.
37. Atkinson S, Valadas E, Smith SM, Lukey PT, Dockrell HM. Monocyte-derived macrophage cytokine responses induced by M. bovis BCG. Tuber Lung Dis 2000 80 : 197 207.
38. Matsumoto H, Suzuki K, Tsuyuguchi K et al. Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG. cytokine regulation and effect of NK cells. Infect Immun 1997 65 : 4405 10.
39. Malmgaard L, Melchjorsen J, Bowie AG, Mogensen SC, Paludan SR. Viral activation of macrophages through TLR-dependent and -independent pathways. J Immunol 2004 173 : 6890 8.
40. Esin S, Batoni G, Pardini M et al. Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Guerin. Immunology 2004 112 : 143 52.
41. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon-γ production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993 90 : 10188 92.
42. Scharton TM, Scott P. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993 178 : 567 77.
43. Theze J, Alzari PM, Bertoglio J. Interleukin 2 and its receptors. recent advances and new immunological functions. Immunol Today 1996 17 : 481 6.
44. Willemsen LE, Hoetjes JP, van Deventer SJ, van Tol EA. Abrogation of IFN-gamma mediated epithelial barrier disruption by serine protease inhibition. Clin Exp Immunol 2005 142 : 275 84.
45. Hayashi T, Morimoto M, Iwata H, Onodera T. Interferon-gamma plays a role in pancreatic islet-cell destruction of reovirus type 2-induced diabetes-like syndrome in DBA/1 suckling mice. Int J Exp Pathol 1998 79 : 313 20.